PubMed HealthSearch

PubMed · 3445658

[IgA nephropathy].

Abstract

Among the chronic glomerulonephritides the IgA-nephropathy is one of the most frequent forms. On account of the possibility of the transition into the terminal renal insufficiency new ways for the therapeutic influence on this disease must be found. In the hitherto used therapy methods above all corticosteroids, cytostatic drugs, inhibitors of thrombocyte aggregation and antiphlogistic drugs were applied. According to the recent investigations from the application of eicosapentaenic acid and the use of plasmapheresis possibilities result to favourably influence the course of the disease and thus to prevent a progression of this disease. By the administration of diphenylhydantoin the IgA-level could, indeed, be lowered, but an influence on the course of the disease could not be proved.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Gläser, K Schirmer. 1987-12-15. [IgA nephropathy].. https://pubmed.ncbi.nlm.nih.gov/3445658/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

IgA nephropathy.

IgAN is the most common type of glomerulonephritis worldwide, and is found more in men and distinctly less in blacks. It presents with macroscopic hematuria in about 40 to 45% of patients, with microscopic hematuria and proteinuria in about 35 to 40%, and with nephrotic syndrome or acute renal failure in the remainder. The diagnosis continues to rely on the finding of the dominant or codominant mesangial deposition of IgA on immunohistologic examination of the kidney. No blood or urine test is sufficiently reliable for diagnosis. While the pathogenesis remains unknown, accumulating evidence suggests that polyclonal stimulation of immunoglobulins perhaps coupled with structural abnormalities of IgA play pivotal roles. These defects may account for the variety of autoantibodies detected in patients with both IgAN and HSP. While IgAN has an indolent course, about 30% of patients will reach ESRD after 20 years, particularly in those who present with hypertension, heavy proteinuria or renal insufficiency. At present, therapy is disappointing, but immunoglobulin supplementation and newer agents that interrupt the pathways of mesangial proliferation and sclerosis hold promise for the future. Kidney transplantation has shown excellent allograft survival.

Glomerulonephritis, IGA